Bipolar I
Resources for Patients and Caregivers
Bipolar I Disorder— defined by manic episodes that last at least 7 days, or by manic symptoms that are so severe that the person needs immediate hospital care. Usually, depressive episodes occur as well, typically lasting at least 2 weeks.
Cluster Number:
Wiki Number: 08-Bipolar I
Diagnosis: This requires just one full manic episode where the individual may be “high” for several days.
US Patients: 1% of the US population in their lifetimes.
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms: Typically it will be followed by one or more depressive stretches of time.
Progression: Relatively good, may last 6 months or 25% go to PTSD or Major Depressive Disorder
Causes:
Medications:Can be reduced by other prescribed drugs.
Therapies:
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- The prevalence and incidence of irritable bowel syndrome and inflammatory bowel disease in depression and bipolar disorder: a systematic review and meta-analysisby Viktoriya L Nikolova on January 24, 2022
CONCLUSIONS: People with depression are at an increased risk of both having and developing lower gastrointestinal disorders. These findings have important implications for how we understand, manage and prevent this comorbidity in clinical practice. Further studies are needed to improve our understanding of the relationship between bipolar disorder and bowel disease as well as the role of psychotropic medication, particularly SSRIs.
- Distinct Effects of Antidepressants in Association With Mood Stabilizers and/or Antipsychotics in Unipolar and Bipolar Depressionby Christophe Moderie on January 24, 2022
PURPOSE/BACKGROUND: There is a dearth of studies comparing the clinical outcomes of patients with treatment-resistant unipolar (TRD) depression and depression in bipolar disorder (BD) despite similar treatment strategies. We aimed to evaluate the effects of the pharmacological combinations (antidepressants [AD], mood stabilizers [MS], and/or antipsychotics [AP]) used for TRD and BD at the McGill University Health Center.
- Service user experiences of care recommendations from the 2014 NICE guideline for bipolar disorder: a surveyby James Roe on January 24, 2022
Clinical guidelines for mental health disorders produced by the National Institute of Care Excellence (NICE) emphasise a recovery-based approach clinical care with collaborative decision-making. The aim of the study was to explore service user experience of collaborative decision-making and recovery focussed care in relation to a NICE clinical guideline for bipolar disorder four years after publication. Participants with a clinical diagnosis of bipolar disorder were recruited from adult mental...
- The Promise of Residential Treatment to Support Functional and Vocational Recovery for Young Adults with Bipolar Disorderby Dagoberto Heredia on January 24, 2022
This case presentation describes how interdisciplinary perspectives can be leveraged to minimize health disparities and improve the quality of life of people living with serious mental illness (SMI). We describe how a young-adult patient with severe Bipolar I Disorder and suicidal behaviors benefited from receiving multi-modal interventions at a residential treatment program with a focus on obtaining competitive employment and independent living. The premise of our model of care is that...